Cladribine comeback

Based on "new data and additional analyses of the compound's benefit-risk profile", Merck is planning to submit cladribine to the EMA for licensing. The development of the drug was stopped in 2011 following potential cancer risks. Merck press release Reuters Cladribine - A to A of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news